May 17, 2020

EasyMed Services launches global website

Swiss-based global medical information technology company
2 min
EasyMed Services launches global website
Swiss-based global medical information technology company EasyMed Services Inc launched its new global website The website has b...

Swiss-based global medical information technology company EasyMed Services Inc launched its new global website

The website has been launched to promote its suite of eHealth and telemedicine applications including International Medical Passport and Easy SmartCare.

Swiss company’s international medical passport makes medical records accessible globally by smartphone.

The International Medical Passport puts complete record on the smartphone together with immediate access to the pre-approved doctors, hospitals and clinics around the world.

The Medical passport works on all phone, PDA and web platforms and operates in more than 80 countries with 300+ mobile carriers.

Another application, Easy SmartCare allows hospitals, clinics and doctors’ practices to communicate with patients through other mobile devices and through text messages on their smartphones. 

The launch of the website represents the first phase of a global communications rollout in all the popular media.

Andy Strote, Partner at Context Creative said, “The EasyMed suite of products answers urgent issues and opportunities brought on by convergence of the global mega trends, the continued rise in healthcare costs, the ongoing growth and advances in the global smartphone market and the opening up of remote areas of the world of travelers.” She also said, “We worked closely with the EasyMed team to ensure that this website effectively communicates the true value of current and future EasyMed products.”

EasyMed Services, Inc is a Swiss-based global medical information technology company that delivers end-to-end patient care solutions through mobile phone PDA and server technologies offering specialized services and applications for healthcare, pharmaceutical and insurance industries.

Share article

Jun 16, 2021

NHS opens 8 clinical trial sites to assess cancer treatment

2 min
NHS and OncoHost to launch clinical trials analysing cancer patients response to immunotherapy

The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy. 

The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment.  They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities. 

Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.

OncoHost, an oncology startup,  will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®

“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.

“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient." 

"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”

Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.

Share article